Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Insulin regulates many aspects of brain function related to mild cognitive impairment (MCI) or dementia, which can be delivered to the brain center via intranasal (IN) devices. Some small, single-site studies indicated that intranasal insulin can enhance memory in patients with MCI or dementia. The pathophysiology of Alzheimer's disease (AD) and diabetes mellitus (DM) overlap, making insulin an attractive therapy for people suffering from MCI or dementia.
Objective: The goal of the study is to evaluate the effectiveness of IN insulin on cognition in patients with MCI or dementia.
Methods: We searched the electronic database for randomized controlled trials (RCTs) that verified the effects of insulin on patients with MCI or dementia.16 studies (899 patients) were identified.
Results: The pooled standard mean difference (SMD) showed no significant difference between IN insulin and placebo groups; however, statistical results suggested a difference between study groups in the effects of ADCS-ADL; AD patients with APOE4 (-) also showed improved performance in verbal memory; other cognitions did not improve significantly.
Conclusion: In view of IN insulin's promising potential, more researches should be conducted at a larger dose after proper selection of insulin types and patients.
Systematic Review Registration: http://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022353546.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512636 | PMC |
| http://dx.doi.org/10.3389/fnagi.2022.963933 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Automatic brain segmentation in cognitive impairment: Validation of AI-based AQUA software in the Southeast Asian BIOCIS cohort.
Ann Acad Med Singap
August 2025
Dementia Research Centre (Singapore), Lee Kong Chian School of Medicine, Nanyang Technology University, Singapore.
Introduction: Interpretation and analysis of magnetic resonance imaging (MRI) scans in clinical settings comprise time-consuming visual ratings and complex neuroimage processing that require trained professionals. To combat these challenges, artificial intelligence (AI) techniques can aid clinicians in interpreting brain MRI for accurate diagnosis of neurodegenerative diseases but they require extensive validation. Thus, the aim of this study was to validate the use of AI-based AQUA (Neurophet Inc.
View Article and Find Full Text PDFPlasma p-tau181 as a Marker of Conversion to Alzheimer's Disease Dementia and Worsening in Cognitive Functions in Subjective Cognitive Decline and Mild Cognitive Impairment: A Longitudinal Study.
Ann Clin Transl Neurol
September 2025
Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Background: Plasma p-tau181 has proven to be a promising diagnostic and prognostic tool in the earliest phases of Alzheimer's disease (AD). We aimed to evaluate the prognostic role of p-tau181 in predicting conversion to AD dementia and worsening in cognition in mild cognitive impairment (MCI) and subjective cognitive decline (SCD).
Methods: We consecutively enrolled 163 patients (50 SCD, 70 MCI, and 43 AD-demented (AD-d)), who underwent plasma p-tau181 analysis with the Simoa assay.
The Impact of Integrating a Parkinson's Specialist Psychiatrist Into the Multidisciplinary Team on Patients With Parkinson's and Cognitive Impairment.
Parkinsons Dis
September 2025
Northumbria Healthcare NHS Foundation Trust, Newcastle Upon Tyne, UK.
Cognitive impairment in Parkinson's disease (PD) is common, but there is scarce evidence as to how this group of patients can be most effectively assessed and managed. Our quality improvement project evaluated the impact of integrating a PD specialist psychiatrist (PDSP) into an existing multidisciplinary team (MDT) to allow direct referral of patients with cognitive impairment rather than to a separate service. We collected data over 1 year to map the referral trajectories of patients through the new pathway and estimated cost savings by comparison with the previous pathway.
View Article and Find Full Text PDFA prediction nomogram for mild cognitive impairment in type 2 diabetes mellitus based on the Chinese visceral adiposity index.
Sci Rep
September 2025
Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, Nanjing, China.
Visceral adiposity has been proposed to be closely linked to cognitive impairment. This cross-sectional study aimed to evaluate the predictive value of Chinese Visceral Adiposity Index (CVAI) for mild cognitive impairment (MCI) in patients with type 2 diabetes mellitus (T2DM) and to develop a quantitative risk assessment model. A total of 337 hospitalized patients with T2DM were included and randomly assigned to a training cohort (70%, n = 236) and a validation cohort (30%, n = 101).
View Article and Find Full Text PDFUse of a Screening Tool for Dementia in a Down Syndrome Specialty Clinic.
Am J Med Genet A
September 2025
Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.
To study the use of a dementia screening tool in our clinic cohort of adults with Down syndrome. To evaluate the functionality of the NTG-EDSD for Dementia as part of a dementia screening protocol for adults with Down syndrome, we conducted a cohort analysis of patients aged 40 and older followed at the Massachusetts General Hospital Down Syndrome Program, noting any clinical interpretation of dementia or mild cognitive impairment (MCI). From September 2023 to September 2024, 54 NTG-EDSD responses were collected.
View Article and Find Full Text PDF